Compare Crispr Therapeutics AG (CRSP) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Virgin Galactic Holdings, Inc. — how do they compare? Crispr Therapeutics AG trades at $50.46 (market cap $4.97B), while Virgin Galactic Holdings, Inc. trades at $2.77 (market cap $335.48M). The key difference: Crispr Therapeutics AG is far larger — about 14.8× Virgin Galactic Holdings, Inc.'s market cap. Which is the better fit depends on your goals.
| CRSP | SPCE | |
|---|---|---|
Market Cap | $4.97B | $335.48M |
Sector | Health | Industrials |
52-Week High | $76.78 | $7.52 |
52-Week Low | $44.34 | $2.17 |
Enterprise Value | $3.32B | $435.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
SPCE trades at $2.42, down 5.84% over 24 hours, reflecting ongoing volatility amid negative profitability. The company reported a net loss of $278.91 million on minimal revenue of $1.54 million in 2025, with cash burn persisting despite narrowing losses. Technical indicators are mixed, with a bearish moving average signal but oversold RSI levels, while analyst consensus is divided with a slight hold bias.
The outlook remains speculative, with opportunities tied to future commercial spaceflight execution, but risks are elevated due to persistent losses, high cash burn, and significant debt. Investor sentiment is cautious, driven by the unproven business model and competitive pressures in the space sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
